Erastin

Catalog No.S7242

For research use only.

Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions of Erastin are best fresh-prepared.

Erastin Chemical Structure

CAS No. 571203-78-6

Selleck's Erastin has been cited by 198 publications

Purity & Quality Control

Choose Selective Ferroptosis Inhibitors

Biological Activity

Description Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions of Erastin are best fresh-prepared.
Targets
Ferroptosis [1]
In vitro

Erastin is selectively lethal to oncogenic RAS-mutant cell lines, and triggers a unique iron-dependent form of non-apoptotic cell death called ferroptosis. [1] [2] Erastin binds directly to VDAC2 and causes mitochondrial damage via ROS production in an NADH-dependent manner, which induces cell death in some tumor cells harbouring activating mutations in the RAS-RAF-MEK pathway. [3] In addition, erastin, via inducing ROS-mediated CID (Caspase-independent cell death), strongly enhances the effect of cisplatin in WT EGFR cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human BJeH cells MkTDSpVv[3Srb36gZZN{[Xl? M{jVeFYhcA>? MkLtTY5lfWO2aX;uJI9nKHKnYXP0bZZmKG:6eXflckB{eGWlaXXzJJBzd2S3Y4Tpc44hcW5iaIXtZY4hSkqnSDDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDSRXMh[W[2ZYKgOkBpenNiYomgSGNHNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcx?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh|MkOyNUc,OjJ6M{KzNlE9N2F-
human BJeLR cells NUfMVJhGS3m2b4TvfIlkyqCjc4PhfS=> MoS3NVAh|ryP M2LwSFEzKGh? NH3FbZFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUmWOUjDj[YxteyCneIDy[ZN{cW6pIGLBV{BIOTKYIH31eIFvfCCjdDCxNEB2VSCjdDCxNkBpenNiYomgeJJ6eGGwIHLseYUhe3SjaX7pcoc> NX2wbWl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N|I{OjFpPkKyPFMzOzJzPD;hQi=>
human BJ cells NUjNSYRpTnWwY4Tpc44h[XO|YYm= NGLLXnI1NjZizszN MUHJcoNz\WG|ZTDpckBqdnS{YXPlcIx2dGG{IH;4bYRifGm4ZTDzdIVkcWW|IHnuJIh2dWGwIFLKJINmdGy|IHX4dJJme3OrbnegWGVTXCxiTGSsJHNVKGGwZDDSRXMhTzF{VjDteZRidnRiZ3Xu[ZMh[2WubIOgZZQhPC54IIXN MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human BJ cells NGK1bFVHfW6ldHnvckBie3OjeR?= M1fpN|kh|ryP NWHG[Wl5UW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gRmoh[2WubIOg[ZhxemW|c3nu[{BVTVKWLDDMWEwhW1RiYX7kJHJCWyCJMULWJI12fGGwdDDn[Y5meyClZXzsd{BifCB7IIXNMi=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human BJ cells M4D1TWZ2dmO2aX;uJIF{e2G7 M1;mSWlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFLKJINmdGy|IHX4dJJme3OrbnegWGVTXCxiTGSsJHNVKGGwZDDSRXMhTzF{VjDteZRidnRiZ3Xu[ZMhcW5icILld4Vv[2Vib3[gWVAyOjZiYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKG2ndHjv[EwhUUN3ME2zNU4zKM7:TT6= NEPEblk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human A673 cells NI\0enBHfW6ldHnvckBie3OjeR?= MmfkTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iQU[3N{Bk\WyuczygSWM2OD1|MDFOwG0v Ml23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human MX2 cells M2XTbmZ2dmO2aX;uJIF{e2G7 MofqTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iTWiyJINmdGy|LDDFR|UxRTF6IN88UU4> M4\i[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human HOS cells MlnsSpVv[3Srb36gZZN{[Xl? M4Sxe2lv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFjPV{Bk\WyuczCsJGVEPTB;MUeg{txONg>? M{HqelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human Hs925.T cells NGG4N3dHfW6ldHnvckBie3OjeR?= M1S1OGlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFjzPVI2NlRiY3XscJMtKEWFNUC9NVch|ryPLh?= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human Hs51.T cells M1rrfWZ2dmO2aX;uJIF{e2G7 NUfKNppWUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gTJM2OS6WIHPlcIx{NCCHQ{WwQVEzKM7:TT6= MlXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human EWS502 cells NH[ydFVHfW6ldHnvckBie3OjeR?= NHLKVnBKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDFW3M2ODJiY3XscJMtKEWFNUC9NVAh|ryPLh?= NEexWJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human BJ cells MULGeY5kfGmxbjDhd5NigQ>? MYPJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDUSXJVKGW6cILld5NqdmdiaIXtZY4hSkpiY3XscJMtKEWFNUC9NVAh|ryPLh?= NYDvXHdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human TC71 cells NITkVmhHfW6ldHnvckBie3OjeR?= MYHJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCWQ{exJINmdGy|LDDFR|UxRTFyIN88UU4> MofNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human U937 cells MX3GeY5kfGmxbjDhd5NigQ>? MXfJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCXOUO3JINmdGy|LDDFR|UxRTFyIN88UU4> NYT2T2lXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human SK-N-MC cells MonmSpVv[3Srb36gZZN{[Xl? MYfJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCVSz3OMW1EKGOnbHzzMEBGSzVyPUGwJO69VS5? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human TC32 cells MlT6SpVv[3Srb36gZZN{[Xl? MnvXTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iVFOzNkBk\Wyucx?= NFrybG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human U2OS cells M4rGT2Z2dmO2aX;uJIF{e2G7 NWPRUm1bUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gWVJQWyClZXzsd{whTUN3ME22JO69VS5? M{DVT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human LNCaP cells NEPSXlBHfW6ldHnvckBie3OjeR?= MlOwTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iTF7DZXAh[2WubIOsJGVEPTB;NjFOwG0v MlXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human Calu1 cells NETUWWRHfW6ldHnvckBie3OjeR?= MlTkTY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3MTDj[YxteyCneIDy[ZN{cW6pIFvSRXMhf2m2aDDhZ5RqfmG2aX7nJI12fGG2aX;ud{BjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[XluIFnDOVA:PCEQvF2u NGjzOI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human SKUT cells NV:2NVdUTnWwY4Tpc44h[XO|YYm= MV;JcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCVS2XUJINmdGy|LDDFR|UxRTRizszNMi=> NVPReHVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human MES-SA cells NVzZfVk3TnWwY4Tpc44h[XO|YYm= M3XLOmlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIF3FV{1USSClZXzsd{whTUN3ME2zJO69VS5? NGXNboI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human SVR cells MWfGeY5kfGmxbjDhd5NigQ>? MXvJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCVVmKgZ4VtdHNuIFXDOVA:Oi53IN88UU4> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human HT1080 cells NUPq[oc3TnWwY4Tpc44h[XO|YYm= NYL5WHh[UW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gTHQyODhyIHPlcIx{KGmwIIDy[ZNmdmOnIH;mJHBFNTl6MEW5JIJ6KHS{eYDhckBjdHWnIHX4Z4x2e2mxbjDt[ZRpd2RuIFnDOVA:OSEQvF2u NFv5cJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human BJ cells MlqwSpVv[3Srb36gZZN{[Xl? MULJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCESjDj[YxteyCneIDy[ZN{cW6pIGTFVnQtKEyWLDDTWEBidmRiUlHTJGcyOlZibYX0ZY51KGenbnXzJINmdGy|IHnuJJBz\XOnbnPlJI9nKFCGLUm4NFU6KGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBu\XSqb3SsJGlEPTB;MD65JO69VS5? NUXRb2FjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human HeLa cells NX3xV4M5TnWwY4Tpc44h[XO|YYm= M4ewNmlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFjlUIEh[2WubIOsJGVEPTB;MD62JO69VS5? MlG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human CCF-STTG1 cells MXLGeY5kfGmxbjDhd5NigQ>? NED3[|hKdmirYnn0bY9vKG:oIGjjeEBqdiCqdX3hckBES0ZvU2TUS|Eh[2WubIOgZZN{\XO|ZXSgZZMh\2y3dHHtZZRmKHKnbHXhd4Uh[W[2ZYKgNkBpenNiYomg[ox2d3KxbXX0dpktKEmFNUC9NE4zKM7:TT6= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG1Okc,OjZ{M{GxOVY9N2F-
Assay
Methods Test Index PMID
Western blot GPX4 / cleaved-PARP / cleaved-caspase3 / LC3 / p62 / LDH / HMGB1 ; TfR1 / p-JNK / JNK / p-P38 ; HSPA5 / p-EIF2AK3 ; GRP78 27308510 31105999 28130223 29383150
Growth inhibition assay Cell survival 29348676
Immunofluorescence HMGB1 31105999

Protocol (from reference)

Cell Research:[1]
  • Cell lines: BJ-TERT/LT/ST/RASV12 cells
  • Concentrations: 5 or 10 μg/mL
  • Incubation Time: 6-11 hours
  • Method: BJ-TERT/LT/ST/RASV12 cells are seeded in 100 mm dishes and allowed to grow overnight. Cells are treated with erastin (5 or 10 μg/ml) for 6, 8, or 11 hr. A camptothecin-treated (0.4 μg/ml) control is maintained, treated at the time of seeding for 20 hours. After the treatment, cells are harvested with trypsin/EDTA and washed once with fresh medium containing serum and then twice with phosphate-buffered saline. Cells are resuspended in 1× binding buffer. 100 μL is incubated with 5 μL of Annexin V-FITC and propidium iodiode for 15 min in the dark at room temperature. Then 400 μl of the 1× binding buffer s added and the cells analyzed by flow cytometry. Data are acquired and analyzed using Cellquest software. Only viable cells that do not stain with propidium iodiode are analzyed for Annexin V-FITC staining using the FL1 channel.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG 300+5%Tween80+ddH2O
For best results, use promptly after mixing.

1.75mg/mL

Chemical Information

Molecular Weight 547.04
Formula

C30H31ClN4O4

CAS No. 571203-78-6
Storage 3 years -20°C powder
1 month -80°C in solvent
Smiles CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Erastin | Erastin supplier | purchase Erastin | Erastin cost | Erastin manufacturer | order Erastin | Erastin distributor